Superfluid Dx
Superfluid Dx, Inc. is a life sciences company developing a high-performance, predictive blood-based diagnostic test for Alzheimer's Disease and related dementias using cell-free messenger RNA (cf-mRNA) analysis and machine learning. Their proprietary platform technology enables non-invasive detection of neurodegenerative diseases at early stages, eliminating the need for invasive procedures like spinal taps and expensive brain scans. The technology allows repeat assessments over time and guides therapy selection, addressing urgent medical needs in Alzheimer's diagnostics. The company is led by experienced executives and scientists, including founders with strong backgrounds in biotech and academia, and is supported by notable investors and grants. Their business model is primarily SaaS and subscription-based, focusing on delivering clinically useful diagnostic tests to healthcare providers and researchers.
Superfluid Dx
Superfluid Dx, Inc. is a life sciences company developing a high-performance, predictive blood-based diagnostic test for Alzheimer's Disease and related dementias using cell-free messenger RNA (cf-mRNA) analysis and machine learning. Their proprietary platform technology enables non-invasive detection of neurodegenerative diseases at early stages, eliminating the need for invasive procedures like spinal taps and expensive brain scans. The technology allows repeat assessments over time and guides therapy selection, addressing urgent medical needs in Alzheimer's diagnostics. The company is led by experienced executives and scientists, including founders with strong backgrounds in biotech and academia, and is supported by notable investors and grants. Their business model is primarily SaaS and subscription-based, focusing on delivering clinically useful diagnostic tests to healthcare providers and researchers.